GEMCITABINE AND CISPLATIN IN UNRESECTABLE MALIGNANT MESOTHELIOMA OF THE PLEURA: A PHASE II STUDY OF THE SOUTHWEST ONCOLOGY GROUP (SWOG 9810)

PURPOSE: The purpose of this open- label phase II SWOG study was to evaluate the activity of gemcitabine (Gemzar ®; Eli Lilly, Indiana, USA) and cisplatin combination therapy, in patients with unresectable malignant mesothelioma of the pleura. PATIENTS AND METHODS: Fifty eligible chemotherapy naïve...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kalmadi, Sujith R., Rankin, Cathryn, Kraut, Michael J., Jacobs, Andrew D., Petrylak, Daniel P., Adelstein, David J., Keohan, Mary Louise, Taub, Robert N., Borden, Ernest C.
Format: Artigo
Langue:Inglês
Publié: 2007
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2702658/
https://ncbi.nlm.nih.gov/pubmed/18006112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2007.09.018
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires